Yasmin, HasinaBakar, Osama Bin Abu2024-06-062024-06-06©202320232023-02ID: 19146094http://hdl.handle.net/10361/23186Cataloged from the PDF version of thesis.Includes bibliographical references (pages 42-48).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.Alzheimer's Disease (AD) is a complex and common neurological disorder and dementia's leading cause. Memantine works to treat moderate to severe AD. This study focused on Food and Drug Administration Adverse Event Reporting System (FAERS) data with the purpose to determine its effect on adverse events of Death and Rhabdomyolysis based on two comparators; the whole database and drug class. To conduct this disproportionality analysis, we have incorporated ROR and 95% CI values. We figured out that memantine possesses a higher mortality benefits ratio than other drugs enlisting both the comparators; whole database and drug class with a value of (ROR = 0.68; CI 95% = 0.46–1.00; P = 0.0483) and (ROR = 0.19; CI 95% = 0.13–0.28; P <0.0001) respectively. In addition, in the cases of rhabdomyolysis, we also find out that memantine has a lower profile assigning both comparators 8.10 (4.48 to 14.67; p < 0.0001); whole database and 2.25 (1.11 to 4.54; P = 0.0241); drug class.61 pagesenBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.Alzheimer’s diseaseNeurological disorderDementiaFAERS databaseFDA adverse event reporting systemRhabdomyolysisAlzheimer's disease--TherapyNervous System DiseasesThesis